argenx Announces Results of Extraordinary General Meeting of Shareholders

Core Points - argenx SE, a global immunology company, held its Extraordinary General Meeting of shareholders on November 18, 2025, to discuss its remuneration policy [1] - The remuneration policy was approved with a significant majority of 95.67%, with 91.1% of share capital represented at the meeting [2] Company Overview - argenx is dedicated to improving the lives of individuals suffering from severe autoimmune diseases and collaborates with leading academic researchers through its Immunology Innovation Program [3] - The company has developed the first approved neonatal Fc receptor (FcRn) blocker and is exploring its potential across various serious autoimmune diseases while advancing several earlier-stage experimental medicines [3]